QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, that the United States (U.S.) Food & Drug Administration (FDA) approved Sucraid®.
single-use containers for patients more than 33 lb (15 kg) with Congenital Sucrase-Isomaltase Deficiency (CSID).
Currently, Sucraid® (sacrosidase) Oral Solution is the only pharmaceutical treatment for CSID in children and adults. Sucraid® is an enzyme replacement therapy for genetically determined sucrase deficiency, which is part of CSID.
Sucraid® helps the breakdown and absorption of sucrose (table sugar) from the intestine, which relieve the gastrointestinal symptoms of CSID. Now Sucraid® is available in both Sucraid® multi-dose bottles and Sucraid® single-use containers. More information can be found at www.sucraid.com.
"If untreated, patients living with this chronic condition suffer from debilitating symptoms. We are always looking for ways to improve their quality of life.
These new single-use containers will make it easier for them to manage their medication," said Weng Tao, MD, PhD, COO of QOL Medical, LLC. "FDA's approval of Sucraid® single-use containers, with three-day room temperature stability, offer greater convenience for CSID patients on the go."
People with CSID are unable to properly digest sucrose (table sugar), which is found naturally in many fruits and vegetables, as well as added to many processed foods.
In adolescents and adults, CSID has been characterized by symptoms of chronic abdominal pain, gas, loose stools, and diarrhea, which overlap with common irritable bowel syndrome (IBS) symptoms. In infants, CSID classically presents as explosive watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools.
Important Safety Information
Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
For more information please visit, www.qolmed.com.